Furthermore, enzalutamide administered orally at 160 mg once daily had anti-tumor activity in Japanese post-chemotherapy patients with CRPC, in terms of best overall response or tumor-shrinking tendency and PSA response. This evidence concerns the gene KLK3 and neoplasm.